J
Julia Hoeng
Researcher at Georgia Institute of Technology
Publications - 230
Citations - 5086
Julia Hoeng is an academic researcher from Georgia Institute of Technology. The author has contributed to research in topics: Medicine & Nicotine. The author has an hindex of 32, co-authored 203 publications receiving 3845 citations.
Papers
More filters
Journal ArticleDOI
Systems toxicology: from basic research to risk assessment.
Shana J. Sturla,Alan R. Boobis,Rex E. FitzGerald,Julia Hoeng,Robert J. Kavlock,Kristin Schirmer,Maurice Whelan,Martin F. Wilks,Manuel C. Peitsch +8 more
TL;DR: Systems Toxicology approaches offer modern strategies for gaining mechanistic knowledge by combining advanced analytical and computational tools, and integrates current knowledge regarding bioanalytical approaches, computational analysis, and the potential for improved risk assessment.
Journal ArticleDOI
Generalized simulated annealing for global optimization: The GenSA package
TL;DR: GenSA as discussed by the authors is a package for generalized simulated annealing to process complicated nonlinear objective functions with a large number of local minima, which can serve as a complementary tool to other widely used R packages for optimization.
Generalized Simulated Annealing for Global Optimization: The GenSA Package Application to Non-Convex Optimization in Finance and Physics
TL;DR: A brief introduction to the GenSA R package is provided and its utility is demonstrated by solving a non-convex portfolio optimization problem in finance and the Thomson problem in physics.
Journal ArticleDOI
Evaluation of the Tobacco Heating System 2.2. Part 1: Description of the system and the scientific assessment program
Maurice Smith,Bruce Clark,Frank Lüdicke,Jean-Pierre Schaller,Patrick Vanscheeuwijck,Julia Hoeng,Manuel C. Peitsch +6 more
TL;DR: The clinical study confirmed the reduced exposure to HPHCs in smokers switching to THS2.2, and the associated transcriptomic study confirmedThe utility of a gene expression signature, consisting of only 11 genes tested in the blood transcriptome of subjects enrolled in the clinical study, as a complementary measure of exposure response.
Journal ArticleDOI
Biology-inspired microphysiological systems to advance patient benefit and animal welfare in drug development
Uwe Marx,Akabane T,Tommy B. Andersson,Elizabeth Baker,Mario Beilmann,Beken S,Brendler-Schwaab S,Murat Cirit,Rhiannon David,Dehne Em,Isabell Durieux,Lorna Ewart,Suzanne Fitzpatrick,Olivier Frey,Florian Fuchs,Linda G. Griffith,Geraldine A. Hamilton,Thomas Hartung,Julia Hoeng,Helena T. Hogberg,David J. Hughes,Donald E. Ingber,Anita R. Iskandar,Toshiyuki Kanamori,Kojima H,Kuehnl J,Marcel Leist,Li B,Peter Loskill,Donna L. Mendrick,Neumann T,Giorgia Pallocca,Ivan Rusyn,Lena Smirnova,Thomas Steger-Hartmann,Danilo A. Tagle,Alexander G. Tonevitsky,Tsyb S,Trapecar M,van de Water B,Van den Eijnden-van Raaij J,Paul Vulto,Watanabe K,Wolf A,Zhou X,Adrian Roth +45 more
TL;DR: It is found that the level of qualification of MPS-based assays for a given context of use and communication gaps between stakeholders are the major challenges slowing industrial adoption by end users, which in turn is causing a regulatory acceptance dilemma.